Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Sionna launches for cystic fibrosis drugs

by Michael McCoy
April 23, 2022 | A version of this story appeared in Volume 100, Issue 14

 

Sionna Therapeutics has officially launched with the closing of a $111 million series B funding. The Boston-based firm was founded in 2019 to develop small molecules that treat cystic fibrosis (CF). Its goal is to restore the function of the CF transmembrane conductance regulator protein, which is defective in CF, by stabilizing the protein’s first nucleotide-binding domain. Among the firm’s leaders are former executives of Biogen, Sanofi, and Vertex Pharmaceuticals, a top player in CF drugs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.